Anti-CD47 H5F9-G4 antibody blocks CD47 – SIRPa interaction and has been shown to restore anti-cancer immunity in mouse models. In recent human studies, initial drug dose showed promising effect and was well tolerated in combination with Rituximab(anti-CD20) with side effects of anemia, headache and fatigue.
